Casdin Capital 13F holdings, Q1 2020
Holdings as of March 31, 2020 · filings on SEC EDGAR · latest filing →
Casdin Capital disclosed 38 US equity positions worth $942.0m in its Q1 2020 13F filing. The largest position was 2655787D at 9.6% of the reported book, followed by SRPT and ALNY. Against the Q4 2019 filing, it opened 8 new positions, added to 12 and reduced 8 among the top 38 holdings.
What did Casdin Capital own in Q1 2020? Top 38 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q4 2019 |
|---|---|---|---|---|---|---|---|
| 1 | 2655787D BLUEPRINT MEDICINES CORP | 9.6% | $90.6m | 1,550,000 | 65% | added | |
| 2 | SRPT SAREPTA THERAPEUTICS INC | Healthcare | 7.0% | $65.5m | 670,000 | 0% | held |
| 3 | ALNY ALNYLAM PHARMACEUTICALS INC | Healthcare | 6.8% | $63.7m | 585,000 | 14% | added |
| 4 | FATE FATE THERAPEUTICS INC | Healthcare | 6.0% | $56.6m | 2,550,000 | 0% | held |
| 5 | CDXS CODEXIS INC | Healthcare | 6.0% | $56.6m | 5,073,780 | 0% | held |
| 6 | BLUEBIRD BIO INC | 5.4% | $50.8m | 1,105,000 | 14% | added | |
| 7 | INVITAE CORP | 5.0% | $47.5m | 3,478,388 | -4% | reduced | |
| 8 | MYOKARDIA INC | 5.0% | $46.6m | 995,000 | -1% | reduced | |
| 9 | AGIO AGIOS PHARMACEUTICALS INC | Healthcare | 4.0% | $38.0m | 1,070,000 | 30% | added |
| 10 | CNST CONSTELLATION PHARMCETICLS I | 3.3% | $30.8m | 980,000 | -19% | reduced | |
| 11 | TWST TWIST BIOSCIENCE CORP | Healthcare | 3.2% | $30.6m | 1,000,000 | 233% | added |
| 12 | RVMD REVOLUTION MEDICINES INC | Healthcare | 3.1% | $28.9m | 1,319,536 | – | new |
| 13 | CDNA CAREDX INC | Healthcare | 3.0% | $28.3m | 1,294,335 | 8% | added |
| 14 | ALEC ALECTOR INC | Healthcare | 2.8% | $26.0m | 1,076,039 | 0% | held |
| 15 | DNLI DENALI THERAPEUTICS INC | Healthcare | 2.7% | $25.5m | 1,455,000 | 16% | added |
| 16 | BLFS BIOLIFE SOLUTIONS INC | Healthcare | 2.5% | $23.5m | 2,468,571 | 0% | held |
| 17 | ADPT ADAPTIVE BIOTECHNOLOGIES COR | Healthcare | 2.3% | $22.0m | 793,125 | 71% | added |
| 18 | MAGENTA THERAPEUTICS INC | 2.0% | $18.7m | 2,971,034 | -4% | reduced | |
| 19 | GLOBAL BLOOD THERAPEUTICS IN | 1.6% | $15.3m | 300,000 | 0% | held | |
| 20 | FULC FULCRUM THERAPEUTICS INC | Healthcare | 1.5% | $14.4m | 1,209,285 | -2% | reduced |
| 21 | GNMK GENMARK DIAGNOSTICS INC | 1.5% | $13.9m | 3,365,000 | 0% | held | |
| 22 | 2JQ GRITSTONE ONCOLOGY INC | 1.4% | $13.2m | 2,270,000 | 5% | added | |
| 23 | GILD GILEAD SCIENCES INC | Healthcare | 1.4% | $13.1m | 175,000 | – | new |
| 24 | CRSP CRISPR THERAPEUTICS AG | Healthcare | 1.2% | $11.3m | 266,430 | – | new |
| 25 | SG7 SAGE THERAPEUTICS INC | 1.2% | $11.1m | 385,000 | 67% | added | |
| 26 | ADVERUM BIOTECHNOLOGIES INC | 1.2% | $11.0m | 1,125,000 | – | new | |
| 27 | VYGR VOYAGER THERAPEUTICS INC | Healthcare | 1.1% | $10.0m | 1,095,075 | 0% | held |
| 28 | ZLAB ZAI LAB LTD | Healthcare | 1.0% | $9.8m | 190,000 | – | new |
| 29 | ALLO ALLOGENE THERAPEUTICS INC | Healthcare | 1.0% | $9.7m | 500,000 | – | new |
| 30 | BRISTOL-MYERS SQUIBB CO | 1.0% | $9.5m | 2,500,000 | 67% | added | |
| 31 | SGMOQ SANGAMO THERAPEUTICS INC | Healthcare | 1.0% | $9.3m | 1,455,000 | 0% | held |
| 32 | ILMN ILLUMINA INC | Healthcare | 0.9% | $8.2m | 30,000 | -50% | reduced |
| 33 | ORCHARD THERAPEUTICS PLC | 0.8% | $7.3m | 975,000 | 19% | added | |
| 34 | BLACK DIAMOND THERAPEUTICS I | 0.8% | $7.2m | 289,395 | – | new | |
| 35 | DECIPHERA PHARMACEUTICALS IN | 0.6% | $5.8m | 140,000 | -45% | reduced | |
| 36 | DERMTECH INC | 0.6% | $5.6m | 571,713 | – | new | |
| 37 | TURNING POINT THERAPEUTICS I | 0.4% | $3.4m | 75,000 | 0% | held | |
| 38 | STOK STOKE THERAPEUTICS INC | Healthcare | 0.3% | $2.7m | 120,000 | -8% | reduced |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.